Resistance mutation info of drug
| Drug General Information | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug ID | D02WVT | |||||||||||||||
| Drug Name | E-3810 | |||||||||||||||
| Synonyms | Lucitanib; AL-3810; E-3810, EOS | |||||||||||||||
| Drug Type | Small molecular drug | |||||||||||||||
| Company | Clovis oncology | |||||||||||||||
| Structure |
|
|||||||||||||||
| Drug Resistance Mutations | ||||||||||||||||
| Target Name | Basic fibroblast growth factor receptor 1 (FGFR1) | Target Info | ||||||||||||||
| Gene Name | FGFR1 | |||||||||||||||
| Uniprot ID | FGFR1_HUMAN | |||||||||||||||
| Species | Homo sapiens | |||||||||||||||
| Reference Sequence |
MWSWKCLLFWAVLVTATLCTARPSPTLPEQAQPWGAPVEVESFLVHPGDLLQLRCRLRDD VQSINWLRDGVQLAESNRTRITGEEVEVQDSVPADSGLYACVTSSPSGSDTTYFSVNVSD ALPSSEDDDDDDDSSSEEKETDNTKPNRMPVAPYWTSPEKMEKKLHAVPAAKTVKFKCPS SGTPNPTLRWLKNGKEFKPDHRIGGYKVRYATWSIIMDSVVPSDKGNYTCIVENEYGSIN HTYQLDVVERSPHRPILQAGLPANKTVALGSNVEFMCKVYSDPQPHIQWLKHIEVNGSKI GPDNLPYVQILKTAGVNTTDKEMEVLHLRNVSFEDAGEYTCLAGNSIGLSHHSAWLTVLE ALEERPAVMTSPLYLEIIIYCTGAFLISCMVGSVIVYKMKSGTKKSDFHSQMAVHKLAKS IPLRRQVTVSADSSASMNSGVLLVRPSRLSSSGTPMLAGVSEYELPEDPRWELPRDRLVL GKPLGEGCFGQVVLAEAIGLDKDKPNRVTKVAVKMLKSDATEKDLSDLISEMEMMKMIGK HKNIINLLGACTQDGPLYVIVEYASKGNLREYLQARRPPGLEYCYNPSHNPEEQLSSKDL VSCAYQVARGMEYLASKKCIHRDLAARNVLVTEDNVMKIADFGLARDIHHIDYYKKTTNG RLPVKWMAPEALFDRIYTHQSDVWSFGVLLWEIFTLGGSPYPGVPVEELFKLLKEGHRMD KPSNCTNELYMMMRDCWHAVPSQRPTFKQLVEDLDRIVALTSNQEYLDLSMPLDQYSPSF PDTRSSTCSSGEDSVFSHEPLPEEPCLPRHPAQLANGGLKRR [Homo sapiens] |
|||||||||||||||
| Targeted Disease | Breast cancer | |||||||||||||||
| Drug Resistance Mutations |
|
|||||||||||||||
| References | ||||||||||||||||
| REF 1 | Illuminating the molecular mechanisms of tyrosine kinase inhibitor resistance for the FGFR1 gatekeeper mutation: the Achilles' heel of targeted therapy.ACS Chem Biol.2015 May 15;10(5):1319-29. | |||||||||||||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.